Vanguard Portfolio Management
KNSA icon

Vanguard Portfolio Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Vanguard Portfolio Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122M Buy
1,911,335
+145,067
+8% +$7.53M 0.01% 1430
2026
Q1 		$85M Buy
+1,766,268
New +$78.2M ﹤0.01% 1499

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Portfolio Management's KNSA Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 8.2% in Q2 2026, buying an estimated $7.53M and bringing the position to 1,911,335 shares worth $122M. The position accounts for 0.01% of the portfolio, ranked #1430.

Vanguard Portfolio Management first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Vanguard Portfolio Management held 1,911,335 shares of Kiniksa Pharmaceuticals worth $122M as of Q2 2026.
  • Vanguard Portfolio Management bought 145,067 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $7.53M.
  • Kiniksa Pharmaceuticals made up 0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1430 holding.
  • Vanguard Portfolio Management first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.